AGARWALEYE500.20

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,846 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
AGARWALEYE
FY26
AKUMS
FY26
ADVENZYMES
FY26
ALIVUS
FY24
Peer
Median
Valuation — at last close
P/E118.81×44.99×20.04×32.52× +265%
P/B7.48×3.45×2.01×2.73× +174%
EV/EBITDA27.67×21.40×11.83×16.61× +67%
Market Cap₹15,846 Cr₹11,483 Cr₹3,382 Cr₹7,433 Cr +113%
Growth
Revenue CAGR 3Y11.32%11.32%
Revenue CAGR 5Y8.24%8.24%
Net Income CAGR 3Y18.68%18.68%
Revenue YoY (latest Q)25.97%13.93%2.08%8.00% +224%
Net Income YoY (latest Q)44.56%56.11%-4.58%25.77% +73%
Profitability
EBITDA Margin27.38%11.98%30.72%29.53%29.53% -7%
Net Income Margin8.08%5.88%23.28%20.62%20.62% -61%
Return on Common Equity6.28%7.66%10.02%20.19%10.02% -37%
Return on Capital Employed8.43%8.44%10.91%25.74%10.91% -23%
Return on Assets4.27%4.71%9.44%16.52%9.44% -55%
Credit & Quality
Total Debt/Equity0.07×0.02×0.01×0.01× +367%
Interest Coverage3.24×3.91×71.91×401.55×71.91× -95%
Scale — latest FY
Revenue / Total Income₹2,080 Cr₹4,359 Cr₹746 Cr₹2,283 Cr₹2,283 Cr -9%
Net Income₹168 Cr₹256 Cr₹174 Cr₹471 Cr₹256 Cr -34%
Total Assets₹3,942 Cr₹5,447 Cr₹1,839 Cr₹2,850 Cr₹2,850 Cr +38%
EPS₹4.21₹16.67₹15.08₹15.88 -73%
Book Value per Share₹66.91₹217.57₹150.38₹183.98 -64%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.